With over 20 years of research experience in druggability of new compounds, NHP disease model and translational medicine, Dr. Zeng founded Primed Shines Biotech in 2013. Prior to founding Primed, she served as Director of China Pharmaceutical Drug Safety Evaluation Center (GLP) for 5 years.Dr. Wen Zeng is a member of the Chinese Pharmacological Society toxicology professional committee, member of the fifth Chinese Veterinary Pharmacopoeia Commission, Expert of new drug review of China Food and Drug Administration (NMPA) and expert of GLP inspection. She worked as PI for more than 20 research and industrial projects. She has accomplished the drug efficacy evaluation of over 100 compounds and over 10 first-in-class drugs have been submitted to FDA and NMPA for IND application. During 2013 and 2017, she has established cooperation with big pharmas including Merck and research institutions such as MRCT and Brown University.

Prior to joining PriMed, Prof. Li was Deputy Director of Laboratory Animal Resource Institute, Safety Evaluation Instate andNational Drug Safety Evaluation Center, Director of Animal Management Department of National Institutes for Food and Drug Control. He currently serves as GLP reviewer for Chinese Food and Drug Administration, committee expert of Non-human Primate Professional Committee and Facility professional committee of Chinese Association for Laboratory Animal Sciences, member of laboratory animal committee of Beijing Science and Technology Committee, Executive Director of Beijing Association for Laboratory Animal Sciences. Prof.  Li has published over 20 papers and edited 6 books regarding management of laboratory animals.He was awarded with the second prize of National Scientific and Technological Progress Award and first prize of Beijing Scientific and Technological Progress Award.

Dr. Gao brings more than 30 years of radiologist experience to his role at Primed. His research and publications focus on cardiovascular research. He came back to China from the US after working at the Johns Hopkins Hospital for 6 years.  He has co-authored over 110 peer-reviewed scientific articles. As CSO, he is in charge of the development and implementation of scientific strategy throughout different departments of Primed. He works as principle investigator for multiple national projects including 7 National Natural Science Foundation Projects and 1 Major Clinical Projects of Ministry of Health. He serves as Vice Chairman of China's Biophysics of Molecular Imaging Committee, and Deputy Head of the molecular imaging group of Chinese Society of Radiology. He also serves on several editorial boards for publications including "International Journal of Magnetic Resonance Imaging", "Chinese Journal of nuclear medicine and molecular imaging", "international medical radiology", "applied Radiology magazine", and "functional and molecular imaging". Second prize of military scientific and technological progress, third prize of national scientific and technological progress.

Dr.Li Gong is in charge of Primed’s overseas projects and disease models development. He started his academic career as a postdoctoral researcher at Fudan University in 2007. Before he joined Sichuan Primed Shines Bio-tech, he worked as Chief Scientific Officer of Center for Safety Study & Evaluation of SINOPHARM Group. As a Study Director, he has over 10 years of experience in safety and efficacy studies using non-human primates, especially ophthalmic diseases, NAFLD/NASH, radiation syndrome, osteoporosis and arthritismodels. He is PI of 5 national studies of pharmaceuticals and basic mechanisms. He has co-authored 30 peer-reviewed scientific articles and edited 2 books in the area of pharmacology.

Xiaoxi Liu is responsible for the administrative, financial, and risk management . Xiaoxi has more than 30 years of experience in legal affairs, financial management as well as finance and investment. His work mainly includes assets appraisal, accounting audit, engineering cost and capital operation. Before cofounding Primed, he worked at College of Mathematics, College of Computer Science of Sichuan University for over 20 years.

Prof. Wang is in charge of the system management of the animal facilities and research laboratories in PriMed. She is also IACUC Chair. Additionally, she is responsible for antitumor efficacy programs.Prior to joining PriMed, Prof. Wang was deputy director of Safety Evaluation Research Center (GLP Center) of China National Pharmaceutical Group. In the meantime, she was deputy director of the pharmaceutical research laboratory of Sichuan Industrial Institute of Antibiotics of China Pharmaceutical Group. She has been engaged in the research of the new drug safety evaluation for 10 years and antitumor efficacy for more than 20 years.

Zunyuan Yang is responsible for leading Primed’s dysmetabolic diseases division. He leads a team focusing on type 2 diabetes, hyperlipidemia, obesity, diabetic nephropathy, non-alcoholic fatty liver diseases NHP models research. He joined Primed in 2013 after he received his M.S. degree from Sichuan Industrial Institute of Antibiotics, majoring in pharmacology.With over 8 years of experience in non-human primates dysmetabolic diseases model sresearch and CRO services management, Zunyuan has worked as Study Director for more than 70 studies in non-human primates in the areas of diabetes and metabolic diseases. He has authored more than 10 papers in peer-reviewed journals.